News Telix to buy radiopharma rival ITM for $1.65bn upfront Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
News Akiram, ITM sign Lutetium-177 supply agreement Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.
News Manufacturing issues mar ITM's radiopharma filing, says FDA ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News Curium strikes $8bn deal to buy radiopharma rival Lantheus Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
News Radiopharma firm AdvanCell raises $315m, and other financing... This week's round-up of private financings in the biotech arena features AdvanCell, alongside Draig, Drug Farm, MindRank AI, and Alchemab.
Oncology Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.